@article{oai:nagasaki-u.repo.nii.ac.jp:00002479,
 author = {Shimada, Midori and Fukuda, Minoru and Fukuda, Masaaki and Kitazaki, Takeshi and Hashiguchi, Kohji and Ikeda, Takaya and Yamaguchi, Hiroyuki and Nakatomi, Katsumi and Ashizawa, Kazuto and Mukae, Hiroshi},
 journal = {OncoTargets and Therapy},
 month = {Jun},
 note = {A 62-year-old female patient with renal dysfunction and pulmonary adenocarcinoma developed postoperative recurrence and received carboplatin/pemetrexed and maintenance pemetrexed. As an anaplastic lymphoma kinase (ALK) gene translocation was identified, the therapy was changed to crizotinib. However, the patient’s blood creatinine level increased, and her physical status worsened. Alectinib also induced exacerbation of renal dysfunction but was controlled by dose reduction of 140 mg twice daily for 2 weeks treatment and 2 weeks break were repeated, and exhibited a partial response for 16 months. Here, we describe the case in which alectinib treatment had beneficial clinical effects on ALK-positive lung adenocarcinoma, which controlled the adverse renal effects by dose reduction and drug breaks., OncoTargets and Therapy, 10, pp.3211-3214; 2017},
 pages = {3211--3214},
 title = {Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction},
 volume = {10},
 year = {2017}
}